Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 11 (Search time: 0.003 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Branford, S.
;
Rudzki, Z.
;
Walsh, S.
;
Grigg, A.
;
Arthur, C.
;
Taylor, K.
;
Herrmann, R.
;
Lynch, K.
;
Hughes, T.
2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Prime, J.
;
Field, C.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Sullivan, B.
;
Briggs, N.
;
Hertzberg, M.
;
Seymour, J.
;
Reynolds, J.
;
Hughes, T.
2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Ross, D.
;
Branford, S.
;
Seymour, J.
;
Schwarer, A.
;
Arthur, C.
;
Yeung, D.
;
Dang, P.
;
Goyne, J.
;
Slader, C.
;
Filshie, R.
;
Mills, A.
;
Vaz de Melo, J.
;
White, D.
;
Grigg, A.
;
Hughes, T.
2015
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
Yeung, D.
;
Osborn, M.
;
White, D.
;
Branford, S.
;
Braley, J.
;
Herschtal, A.
;
Kornhauser, M.
;
Issa, S.
;
Hiwase, D.
;
Hertzberg, M.
;
Schwarer, A.
;
Filshie, R.
;
Arthur, C.
;
Kwan, Y.
;
Trotman, J.
;
Forsyth, C.
;
Taper, J.
;
Ross, D.
;
Beresford, J.
;
Tam, C.
;
et al.
2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
Hughes, T.
;
Kaeda, J.
;
Branford, S.
;
Rudzki, Z.
;
Hochhaus, A.
;
Hensley, M.
;
Gathmann, I.
;
Bolton, A.
;
van Hoomissen, I.
;
Goldman, J.
;
Radich, J.
2003
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR
Hui, C.
;
Goh, K.
;
White, D.
;
Branford, S.
;
Grigg, A.
;
Seymour, J.
;
Kwan, Y.
;
Walsh, S.
;
Hoyt, R.
;
Trickett, A.
;
Rudzki, Z.
;
Ma, D.
;
To, L.
;
Hughes, T.
2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Hughes, T.
;
Hochhaus, A.
;
Branford, S.
;
Muller, M.
;
Kaeda, J.
;
Foroni, L.
;
Druker, B.
;
Guilhot, F.
;
Larson, R.
;
O'Brien, S.
;
Rudoltz, M.
;
Mone, M.
;
Wehrle, E.
;
Modur, V.
;
Goldman, J.
;
Radich, J.
2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Muller, M.
;
Cortes, J.
;
Kim, D.
;
Druker, B.
;
Erben, P.
;
Pasquini, R.
;
Branford, S.
;
Hughes, T.
;
Radich, J.
;
Ploughman, L.
;
Mukhopadhyay, J.
;
Hochhaus, A.
2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Branford, S.
;
Rudzki, Z.
;
Walsh, S.
;
Parkinson, I.
;
Grigg, A.
;
Szer, J.
;
Taylor, K.
;
Hermann, R.
;
Seymour, J.
;
Arthur, C.
;
Joske, D.
;
Lynch, K.
;
Hughes, T.
2010
Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Cortes, A.
;
Baccarani, M.
;
Guilhot, F.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Pasquini, R.
;
Goldberg, S.
;
Kalaycio, M.
;
Moiraghi, B.
;
Rowe, J.
;
Tothova, E.
;
de Souza, C.
;
Rudoltz, M.
;
Yu, R.
;
Krahnke, T.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
Discover
Author
10
Hughes, T.
5
Radich, J.
4
Arthur, C.
4
Grigg, A.
4
Rudzki, Z.
4
Seymour, J.
4
White, D.
3
Druker, B.
3
Hochhaus, A.
3
Ross, D.
.
next >
Subject
11
Female
11
Humans
11
Male
11
Middle Aged
10
Aged
10
Benzamides
10
Imatinib Mesylate
10
Leukemia, Myelogenous, Chronic, B...
10
Piperazines
7
Antineoplastic Agents
.
next >
Date issued
6
2010 - 2015
5
2002 - 2009